Thank you very much, Mr. Chair.
Thank you all for coming here today. I have so many questions for you, so I'm going to try to get right to it.
You mentioned the government's recent budget, and how the government offered tax incentives to generic and brand-name pharmaceuticals that donate medicines overseas. Can you tell us what sort of impact this change may have overall in terms of Canada's access-to-medicines regime, and particularly for CAMR and your company? Is it going to have any effect there?